On Friday, the FDA authorized AbbVie Inc.s and Danish pharmaceutical Genmabs blood cancer medication for adult patients who have had at least two prior lines of treatment. The new medication, Epcoritamab, belongs to a class known as bispecific antibodies, which employ complex therapeutic proteins with the ability to attach to the bodys immune cells and assault cancer cells.

Epcoritamab, to be marketed under the trade name Epkinly, was developed to treat a kind of advanced large B-cell lymphoma, a malignancy that begins in white blood cells. The FDA clearance makes epcoritamab the first of its kind for the condition, which has around 150,000 new cases each year worldwide.

Mr. Yaron Werber, TD Cowen analyst, stated that the key benefits of epcoritamab are the best-in-class effectiveness and convenience of subcutaneous (under the skin) administration. He revealed that the FDA approval was based on the results of a mid-stage study, which showed that an injection of epcoritamab under the skin benefited 63% of patients whose cancer shrank or vanished following therapy. 

(Source: https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/us-fda-approves-genmab-abbvies-blood-cancer-therapy/100368054 )